INTRODUCTION
Prostate cancer is a leading cause of cancer mortality in men worldwide. 1 Nearly all prostate cancer-specific deaths occur after the development of metastatic castration-resistant prostate cancer (mCRPC). 2 Approximately 90% of patients with mCRPC develop bone metastases, the predominant cause of morbidity in this population. [3] [4] [5] [6] Docetaxel is standard first-line chemotherapy for mCRPC based on improvements in progressionfree (PFS) and overall survival (OS) compared with mitoxantrone plus prednisone. 3, 7, 8 Two androgen pathway inhibitors, abiraterone acetate and enzalutamide, improved PFS and OS in patients with mCRPC when administered before 9, 10 or after chemotherapy. 11, 12 Significant OS benefit in patients with mCRPC has also been reported with sipuleucel-T, an autologous active cellular immunotherapy, radium-223, and cabazitaxel in combination with prednisone after progression during treatment with docetaxel. [13] [14] [15] However, despite recent advances in clinical management, the prognosis for patients with mCRPC remains poor. 16, 17 The receptor tyrosine kinase METand the vascular endothelial growth factor (VEGF) signaling pathways seem to have important roles in prostate cancer development and progression. 18 MET expression in prostate cancer was greater in bone metastases than in primary tumors and lymph node metastases. [18] [19] [20] The VEGF pathway regulates cell proliferation, migration, differentiation, and survival through expression on osteoblasts and osteoclasts. Both MET and VEGF are thought to be involved in bone formation and remodeling. [18] [19] [20] Cabozantinib is an orally bioavailable inhibitor of tyrosine kinases, including MET and VEGF receptor 2. Cabozantinib has shown activity in preclinical models of many tumor types, including prostate cancer. [21] [22] [23] [24] In a phase II, placebo-controlled, randomized discontinuation trial, cabozantinib demonstrated preliminary evidence of activity in multiple tumor types, including prostate cancer. 25 In patients with mCRPC, cabozantinib was associated with improvement in PFS (hazard ratio [HR] , 0.12; P , .001) and reductions in soft tissue lesions, bone turnover markers, pain, and narcotic use; the observed safety profile was consistent with other VEGF tyrosine kinase inhibitors (TKIs). 25 In a subsequent nonrandomized expansion cohort of patients with mCRPC who had bone metastases and disease progression after docetaxel, cabozantinib (100 or 40 mg per day) resulted in dramatic improvement in bone scans, pain, analgesic use, measurable soft tissue disease, circulating tumor cell (CTC) conversion, and bone biomarkers. 26, 27 On the basis of the promising clinical activity observed in patients with previously treated mCRPC, we conducted a phase III study of cabozantinib versus prednisone in men with mCRPC, bone metastases, and disease progression after docetaxel and abiraterone acetate and/or enzalutamide. The primary end point was OS, and bone scan response (BSR) at 12 weeks was the key secondary end point.
PATIENTS AND METHODS

Patients
The study enrolled patients age 18 years or older with mCRPC who had bone metastases and disease progression after docetaxel and abiraterone acetate and/or enzalutamide. There was no limit on the number of prior anticancer treatments. Eligible patients had documented histologic or cytologic diagnosis of adenocarcinoma of the prostate, serum testosterone levels lower than 1.75 nmol/L, and evidence of bone metastases related to prostate cancer on bone scans from a protocol-credentialed scanner within 28 days before random assignment. Disease progression after prior therapy was defined as prostate-specific antigen (PSA) progression according to modified Prostate Cancer Working Group 2 criteria 28 or radiographic progression in soft tissue or bone lesions. Eligible patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2 and adequate organ and bone marrow function. Exclusion criteria are summarized in the Appendix (online only).
The study was approved by the institutional review board or ethics committee at each center and was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. An independent data monitoring committee monitored the study.
Study Design
This was a phase III, multicenter, randomized, double-blind controlled trial. Patients were randomly assigned at a two-to-one ratio to either cabozantinib or prednisone. Random assignment was stratified by prior cabazitaxel (yes v no), baseline pain severity (worst pain by Brief Pain Inventory item 3 of , 4 v $ 4), and ECOG PS (0 to 1 v 2). Random assignment and blinding procedures are summarized in the Appendix.
Cabozantinib was administered orally at 60 mg once per day along with oral prednisone-matched placebo administered twice per day. Prednisone was administered orally at 5 mg twice per day along with oral cabozantinib-matched placebo administered once per day. Patients continued study treatment as long as clinical benefit was experienced as determined by the investigator and as long as they did not experience unacceptable toxicity or meet other protocol-specified criteria. Patients were observed until death or until the sponsor's decision to no longer collect these data.
Dose reductions (from 60 to 40 mg and 40 to 20 mg) or interruptions of cabozantinib or matched placebo treatment were allowed for unacceptable adverse events (AEs). Dose modification details are further summarized in the Appendix.
End Points and Assessments
The primary end point was OS. The secondary end point was BSR at week 12, defined as a decrease of 30% or more in bone scan lesion area from baseline to week 12, which was evaluated by a central independent radiology review committee. 29 Progressive disease on bone scan was defined as an increase of more than 30% from baseline in bone scan lesion area in areas attributable to metastatic disease or at least two new areas of radiotracer uptake attributable to metastatic disease in regions of bone not previously showing radiotracer uptake. Further information on BSR measurement and assessment is provided in the Appendix. Radiographic PFS (rPFS) was determined according to RECIST (version 1.1).
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Exploratory efficacy assessments included rPFS per investigator assessment, changes in CTCs, bone biomarkers, circulating PSA, and symptomatic skeletal events (SSEs). Exploratory end point assessments are summarized in the Appendix.
Safety assessments included monitoring of AEs and serious AEs (SAEs), deaths, standard laboratory test results, physical examination findings, and ECG recordings. Safety was assessed at least every 3 weeks up to week 12 (based on date of first dose) and every 6 weeks thereafter. AE terms were mapped to system organ class and preferred terms using the Medical Dictionary for Regulatory Activities (version 16.1). The seriousness, severity grade, and relationship of AEs to study treatment were assessed by the investigator, and severity grade was defined by the Common Terminology Criteria for Adverse Events (version 4.0).
Statistical Methods and Analysis
The study assumed a 7.0-month median OS for the control group based on the observed OS in the COU-AA-301 study. 12 On the basis of a random assignment ratio of two to one of cabozantinib to prednisone, 578 deaths were required to provide 90% power to detect an HR of 0.75 (median OS, 7.0 months in prednisone group v 9.3 months in cabozantinib group) using the log-rank two-sided test at an overall type I error level of 0.05.
The primary analysis of OS was conducted using the intent-to-treat population. The median duration of OS and the associated 95% CI for each treatment group were estimated using the Kaplan-Meier method. Inference testing was conducted using the log-rank test, stratified by the same factors used to stratify the random assignment. The HR and 95% CI were estimated using a Cox proportional hazards model, with treatment group as the independent variable, and stratified by random assignment stratification factors. P values are presented without control for multiple comparisons.
The percentage dose-intensity of cabozantinib was calculated as 100 3 (average daily dose [mg/day])/(60 mg/day), and the percentage dose-intensity of prednisone was calculated as 100 3 (average daily dose [mg/day])/(10 mg/day). Analysis plans for secondary or exploratory end points and prespecified subgroups are described in the Appendix.
Prespecified subgroup analyses for both the primary and secondary end points evaluated the influence of baseline and demographic characteristics on outcomes, including region (North America, Europe, or Australia), prior cabazitaxel therapy (yes v no), visceral metastases (yes v no), baseline Brief Pain Inventory item 3 (, 4 v $ 4), ECOG PS (0 to 1 v 2), and lactate dehydrogenase (# upper limit of normal v . upper limit of normal).
RESULTS
Patients
Between July 2, 2012, and November 14, 2014, 1,028 patients were enrolled at 216 centers across 14 countries in Europe (76%), North America (15%), and Australia (6%). Baseline characteristics were balanced between treatment groups (Table 1) . A majority of patients were age 65 years or older, white, and enrolled in Europe. Random assignment stratification factors were balanced between treatment groups.
Patient disposition is summarized in Figure 1 . A total of 1,023 patients received treatment: 680 received cabozantinib, and 343 received prednisone. As of July 7, 2014, 91% of patients in the cabozantinib group and 95% in the prednisone group had discontinued study treatment. Discontinuations because of AEs were more common with cabozantinib (33%) than with prednisone (12%). Discontinuations because of progressive disease were more common with prednisone (37%) than with cabozantinib (19%). Other primary reasons for discontinuation were similar between treatment groups.
OS
The primary and final OS analysis was conducted after 614 events had occurred. Median OS estimated by Kaplan-Meier methods was 11.0 months for cabozantinib and 9.8 months for prednisone. No significant difference in OS between cabozantinib and prednisone was observed (HR, 0.90; 95% CI, 0.76 to 1.06; stratified log-rank P = .213; Fig 2A) . Prespecified subgroup analyses for OS are summarized in the Appendix (Appendix Fig A1, online only). BSR BSR at week 12 per independent radiology review committee was 42% (95% CI, 38% to 46%) with cabozantinib and 3% (95% CI, 1% to 5%) with prednisone (unstratified and stratified Cochran-Mantel-Haenszel P , .001 for both; Table 2 ). For patients with a BSR (n = 286), median duration of BSR (calculated from date of first BSR to date of bone scan progression) was 5.8 months (95% CI, 5.5 to 8.3) with cabozantinib and 1.8 months (95% CI, 0.62 to not estimable) with prednisone.
PFS
Cabozantinib was associated with improvements in investigatordetermined rPFS. Median rPFS was 5.6 months with cabozantinib and 2.8 months with prednisone (HR, 0.48; 95% CI, 0.40 to 0.57; stratified log-rank P , .001; Fig 2B) . Subsequent therapies received after progression were more common in the cabozantinib arm than in the prednisone arm (Table 3) .
Skeletal-Related Events
Fifty-two percent of patients in the cabozantinib group and 54% of patients in the prednisone group had experienced one or more SSEs before study entry. Cabozantinib treatment was associated with an increase in time to first SSE (HR, 0.62; 95% CI, 0.48 to 0.81; stratified log-rank P , .001; Fig 2C) and with lower rates of SSEs during study (cabozantinib, 14%; prednisone, 21%; Appendix Table A1 , online only). Radiotherapy to bone was the most common SSE in both groups (cabozantinib, 12%; prednisone, 18%).
CTCs, Bone Biomarkers, and PSA
The favorable CTC conversion rate (defined as $ five CTCs at baseline to , five CTCs as best postbaseline result) was 33% for cabozantinib and 6% for prednisone (Appendix Table A2 , online only). Cabozantinib treatment was also associated with improvement in bone-specific alkaline phosphatase, N-terminal cross-linked telopeptides of type I collagen, and C-terminal cross-linked telopeptides of type I collagen (Appendix Table A3 , online only). Cabozantinib treatment was not associated with improved PSA response or time to PSA progression. A PSA response, defined as a reduction of 50% or more in PSA level, occurred in 6% of cabozantinib-treated patients and 2% of prednisone-treated patients. The median time to PSA progression was 4.2 and 3 months with cabozantinib and prednisone, respectively (unstratified HR, 0.95; P = .639).
Safety
The median duration of study drug treatment was 20.1 weeks (range, 0.6 to 92.1 weeks) for cabozantinib and 12.3 weeks (range, Received study treatment (safety population) (n = 343; 99%)
Continued study treatment (safety population) (n = 14) Overall Survival (probability) 2.0 to 71.1 weeks) for prednisone. The median percentage doseintensity was 75% for cabozantinib and 100% for prednisone.
The most common AEs in both groups are listed in Table 4 . SAEs were reported by 62% and 53% of patients in the cabozantinib and prednisone groups, respectively. The following SAEs occurred at an incidence of at least 2% higher with cabozantinib compared with prednisone: pulmonary embolism (6.2% v 0.9%), vomiting (4.1% v 1.8%), fatigue (2.9% v 0.9%), and dehydration (2.9% v 0.3%).
Study drug discontinuations because of AEs were reported for 33% and 12% of patients in the cabozantinib and prednisone groups, respectively (Appendix Table A4 , online only). AEs leading to dose reductions or interruptions were reported for 88% and 45% of patients in the cabozantinib and prednisone groups, respectively, and AEs that led to dose reductions were reported for 67% and 15% of patients, respectively. The median time to first dose level reduction was 47.5 days (range, 6 to 379 days) and 44 days (range, 22 to 344 days) in the cabozantinib and prednisone groups, respectively. AEs leading to dose modifications are summarized in Appendix Table A5 (online only).
Grade 5 AEs occurring within 30 days of the last study drug dose were reported in 15% and 13% of patients in the cabozantinib and prednisone groups, respectively, and were most commonly considered disease related. Deaths considered not related to prostate cancer and occurring within 30 days of the last study dose are summarized in the Appendix.
DISCUSSION
In this randomized, controlled trial of men with mCRPC and bone metastases with disease progression after docetaxel and abiraterone acetate and/or enzalutamide, cabozantinib did not significantly improve OS compared with prednisone. Consistent with observations from phase II studies, 25,26 cabozantinib was associated with improvements in other study outcomes, including BSR, rPFS, SSEs, CTCs, and bone biomarkers, but not PSA outcomes.
The primary results of this study are consistent with the published results of sunitinib, an orally available TKI that inhibits VEGF receptor 2 but not MET. In phase II studies of patients with mCRPC, sunitinib was observed to have modest effects on bone scans and bone biomarkers. 31 In a phase III randomized controlled trial of patients with mCRPC and disease progression after docetaxel, sunitinib did not improve OS compared with placebo (HR, 0.914; 95% CI, 0.762 to 1.097; P = .168).
32 Sunitinib was associated with significant improvement in PFS (HR, 0.725; 95% CI, 0.591 to 0.890; P , .001) and higher rates of study drug discontinuation because of AEs (27% v 7%) compared with placebo. The phase III sunitinib study did not report effects on bone scans, CTCs, or bone biomarkers. Other compounds targeting VEGF and angiogenesis, such as bevacizumab, afilbercept, and lenalidomide, have also failed to improve OS in patients with mCRPC when combined with docetaxel. [33] [34] [35] No significant anticancer activity was detected with the MET-targeting agent rilotumumab when combined with mitoxantrone.
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In metastatic prostate cancer, CTC counts at baseline have prognostic value, and changes during therapy have been considered predictive of treatment benefit. 37-39 Furthermore, higher CTC counts have been observed in patients with bone metastases compared with those without bone metastases.
37,40
In our study, a higher incidence of CTC conversion, from five or more cells at baseline (indicative of unfavorable prognosis) to fewer than five cells postbaseline (indicative of favorable prognosis), in the cabozantinib group compared with the prednisone group was observed. These findings, along with favorable changes in other biomarkers, except PSA, support the hypothesis that cabozantinib treatment was associated with biologic activity affecting both tumor cells and the bone microenvironment.
The biologic activities of cabozantinib are diverse, with bone effects, direct effects on cancer cells, and antiangiogenic effects being demonstrated in preclinical models. [21] [22] [23] It could be argued that the observed changes in BSR, bone biomarkers, and SSEs in our study are consistent with biologic effects in bone and bone metastases, and the improvements in CTCs suggest a direct antitumor effect, although the lack of improvement in PSA outcomes argues against such an effect. On the basis of phase II study results, it was clear that the effects of cabozantinib on intermediate end points were complex and in some cases contradictory. For these reasons, OS was selected as the primary study end point. The cabozantinib dose selected in this trial was based on findings from a phase II expansion cohort in patients with mCRPC who received either 100 or 40 mg of cabozantinib per day. 27 Both doses showed activity in late-stage mCRPC, with improved tolerability at the 40-mg dose. In another study, the 40-mg dose showed substantial pharmacodynamic activity for BSR, whereas activity seemed markedly attenuated at a 20-mg dose. 41 Therefore, a dose of 60 mg per day was selected for phase III investigation in mCRPC as an active dose that could be reduced to 40 mg for tolerability while still maintaining pharmacodynamic activity.
Safety data in this trial were consistent with those observed in earlier-stage cabozantinib trials in mCRPC, 25, 27 and no new or unexpected AEs occurred. Adverse effects typically associated with VEGF inhibition and/or TKI use, such as hypertension, fatigue, and palmar-plantar erythrodysesthesia syndrome, were observed at higher rates with cabozantinib compared with prednisone. The pulmonary embolism incidence with cabozantinib was consistent with that previously described in phase II trials in patients with mCRPC treated with agents targeting the VEGF pathway. 25, 27 Dehydration was also observed in this population, and this may have been associated with the higher incidence of GI disorders (eg, diarrhea, nausea, and vomiting) with cabozantinib treatment. Sixty-seven percent of patients had AEs that led to dose reductions, a rate lower than that observed in a phase III trial of a higher dose of cabozantinib (140 mg/day) in patients with metastatic medullary thyroid cancer, whereas the rate of treatment discontinuation because of AEs with cabozantinib was substantially higher in our study (33% v 16%). 42 These results indicate insufficient tolerability of the 60-mg dose of cabozantinib in our older patient population with heavily pretreated mCRPC, and lower doses and/or more proactive management of AEs should be considered in future investigations.
It is unclear why improvements in BSR, rPFS, SSEs, CTC conversions, and bone biomarkers with cabozantinib did not translate into significantly improved OS in this population of patients with late-stage mCRPC. Notably, the relationship between intermediate outcomes and OS may vary from drug to MET overexpression has been shown to be more common in metastatic sites compared with primary prostate cancer samples. 43 Aberrant expression of hepatocyte growth factor, the MET ligand, has also been shown to promote tumor progression in preclinical studies, and high plasma levels of hepatocyte growth factor have been correlated with poor outcomes in patients with prostate cancer. 44, 45 The successful development of cabozantinib in mCRPC may require a specific biomarker evaluation to identify patients with a high likelihood of treatment benefit.
In summary, cabozantinib did not significantly improve OS in patients with mCRPC and disease progression after docetaxel and abiraterone acetate and/or enzalutamide. Cabozantinib was not associated with improvements in PSA outcomes. However, improvements in other study outcomes, including BSR, rPFS, time to first SSE, CTC conversions, and bone biomarkers, are notable. cross-linked telopeptides of type I collagen), patients were assessed for best change (greatest decrease or lowest increase) at weeks 6 and/or 12.
Assessment of Skeletal-Related Events
Symptomatic skeletal events (SSEs) were defined as any one of the following: radiation therapy to bone including the use of bone-targeted radiopharmaceuticals, pathologic fracture, spinal cord compression, or bone surgery. Any SSEs occurring in the previous 12 months or within a longer timeframe but that were considered clinically significant were recorded at baseline. For postbaseline assessments, the investigator determined whether an SSE had occurred, and a description of the event was recorded.
Assessment of Overall Survival
Duration of overall survival was defined as the time from random assignment to death resulting from any cause. For patients who were alive at the time of data cutoff or who were permanently lost to follow-up, duration of overall survival was right-censored at the earlier of the data cutoff date or the date the patient was last known to be alive.
Subgroup Analyses
Prespecified subgroup analyses for both the primary and secondary end points evaluated the influence of baseline and demographic characteristics on outcome, including region (North America, Europe, or Australia), prior cabazitaxel therapy ( 
Assessment of Secondary End Point
For the secondary analysis of the proportion of patients experiencing a bone scan response (BSR) according to IRC assessment at the end of week 12, a stratified two-sided Cochran-Mantel-Haenszel test at the .05 level of significance was used to compare the two treatment groups, using the same stratification factors as those used for the random assignment schedule. A gatekeeping strategy for analysis of the secondary efficacy end point controlled the family-wise error rate at 0.05.
Assessment of Exploratory End Points
Each exploratory end point was analyzed using an appropriate two-sided statistical test without adjustment for multiplicity. Exploratory analyses of BSR included best BSR at any time point and duration of BSR. The hazard ratio was estimated using a Cox regression model with treatment arm as the only main effect and stratifying by the same stratification factors used for random assignment. Descriptive statistics were performed for CTC conversion, and categorical analyses were also performed. The median time to first SSE and the associated 95% CI for each treatment arm were estimated using the Kaplan-Meier method.
PSA Responses
Blood samples for PSA analysis were collected at screening, the end of week 12 after the date of random assignment, and every 12 weeks thereafter and assessed at a central laboratory.
Causes of Death Through 30 Days of Last Dose of Study Drug
The most common causes of death (occurring in $ two patients in either treatment arm) through 30 days of the last dose of study drug were prostate cancer (cabozantinib, n = 50; prednisone, n = 26), general physical health deterioration (n = 14; n = 1), death not otherwise specified (n = 4; n = 1), sepsis (n = 3; n = 1), euthanasia (n = 3; n = 0), pulmonary embolism (n = 3; n = 0), multiorgan failure (n = 2; n = 2), pneumonia (n = 2; n = 1), renal failure (n = 2; n = 1), septic shock (n = 2; n = 1), respiratory failure (n = 2; n = 0), cardiac failure (n = 1; n = 1), and sudden death (n = 1; n = 1). Abbreviation: CTC, circulating tumor cell. *Best postbaseline value defined as the smallest value across week 6 and week 12 postbaseline visits. Abbreviations: BSAP, bone-specific alkaline phosphatase; CTx, C-terminal cross-linked telopeptides of type I collagen; NTx, N-terminal cross-linked telopeptides of type I collagen; LLQ, lower limit of quantitation. *Best change was the largest decrease, or smallest increase if no decrease was observed, at weeks 6 and 12 from baseline. †NTx and CTx percentages were based on patients with baseline value $ LLQ. Regarding patients , LLQ at baseline, no patient in the cabozantinib arm or the prednisone arm converted to $ LLQ at any time postbaseline. For BSAP, all but one patient was $ LLQ at baseline. 
